Efficiency of Autologous Amniotic Fluid Injection in the Healing of Cesarean Section Scar in High-Risk Population
NCT ID: NCT06531356
Last Updated: 2024-08-01
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
108 participants
INTERVENTIONAL
2024-02-16
2024-05-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Platelet Rich Plasma and Wound Healing After Cesarean Section
NCT04669353
Cesarean Scar Evaluation Using Saline Infusion Sonography in Women With Previous Pregnancy in Scar
NCT05672563
2D and 3D Ultrasound Assessment of Cesarean Section Scars
NCT03111706
Cesarean Scar Characteristics After Scheduled and Emergency Cesarean Deliveries
NCT03609281
The Effect of Pre-incisional Local Xylocaine Injection on Post Operative Pain and Scar Formation After Cesarean Section
NCT00914498
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cases
autologous amniotic fluid
10 cc of amniotic fluid aspirated after opening uterine incision in cesarean section, then Injected in edges of skin before closure
control
No amniotic fluid injected in skin edges
conventional closure of skin
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
autologous amniotic fluid
10 cc of amniotic fluid aspirated after opening uterine incision in cesarean section, then Injected in edges of skin before closure
No amniotic fluid injected in skin edges
conventional closure of skin
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Anemic patients
* Maternal chronic disease e.g., Diabetes and Hypertension
* BMI of \> 25 Kg/m2.
* Underwent previous CS.
Exclusion Criteria
* No previous section.
* Anhydraminos.
* Congenital malformation of the fetus.
30 Years
45 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Kasr El Aini Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Hend Mahmoud Abdelghany
Lecturer of Obstetrics and Gynecology, Cairo University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
kasr Al Aini, Faculty of Medicine, Cairo University
Cairo, Old Cairo, Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
MS-141-2023
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.